NASDAQ:ONCO Onconetix (ONCO) Stock Price, News & Analysis $3.58 -0.04 (-1.10%) As of 10:02 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Onconetix Stock (NASDAQ:ONCO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Onconetix alerts:Sign Up Key Stats Today's Range$3.45▼$3.6550-Day Range$3.44▼$7.1752-Week Range$3.16▼$656.88Volume19,665 shsAverage Volume225,748 shsMarket Capitalization$1.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio. Read More Onconetix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreONCO MarketRank™: Onconetix scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Onconetix. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioOnconetix has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Onconetix's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.82% of the float of Onconetix has been sold short.Short Interest Ratio / Days to CoverOnconetix has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Onconetix has recently increased by 100.88%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOnconetix does not currently pay a dividend.Dividend GrowthOnconetix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.82% of the float of Onconetix has been sold short.Short Interest Ratio / Days to CoverOnconetix has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Onconetix has recently increased by 100.88%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News SentimentN/A News SentimentOnconetix has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Onconetix this week, compared to 1 article on an average week.Search Interest1 people have searched for ONCO on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Onconetix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.10% of the stock of Onconetix is held by insiders.Percentage Held by InstitutionsOnly 23.89% of the stock of Onconetix is held by institutions.Read more about Onconetix's insider trading history. Receive ONCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconetix and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCO Stock News Headlines$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. (NASDAQ: ONCO)July 17, 2025 | globenewswire.comOnconetix, Inc.: Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreementJuly 16, 2025 | finanznachrichten.deAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and searches — are feeding the next wave of AI innovation. Big Tech is harvesting it. Mode Mobile is giving it back to you. They are creating a user-powered data economy that shares the upside, and +50M users have already generated +$325M in earnings. This isn't a theory… Mode’s 32,481% revenue growth from 2019-2022 landed them the #1 spot on Deloitte’s 2023 list of fastest growing companies in software, and they’ve secured the Nasdaq ticker $MODE ahead of a potential IPO. The offering could close any moment now. AI breakthroughs are everywhere, but these models need your data to survive. Invest in the company that allows you to share in the profits from yours.July 30 at 2:00 AM | Mode Mobile (Ad)Onconetix Shares Touch All-Time Low on Reverse Merger With OcuvexJuly 16, 2025 | marketwatch.comONCO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Onconetix, Inc. Is Fair to ShareholdersJuly 16, 2025 | businesswire.comOnconetix and Ocuvex Therapeutics announce execution of definitive merger agreementJuly 16, 2025 | globenewswire.comOnconetix, Inc. Announces Positive Decision by Nasdaq Hearings PanelJune 16, 2025 | globenewswire.comOnconetix, Inc. Announces Approval of 1-for-85 Reverse Stock Split by StockholdersJune 13, 2025 | nasdaq.comSee More Headlines ONCO Stock Analysis - Frequently Asked Questions How have ONCO shares performed this year? Onconetix's stock was trading at $53.55 on January 1st, 2025. Since then, ONCO shares have decreased by 93.3% and is now trading at $3.58. How were Onconetix's earnings last quarter? Onconetix, Inc. (NASDAQ:ONCO) released its quarterly earnings data on Thursday, June, 12th. The company reported $21.25 EPS for the quarter. The company earned $0.10 million during the quarter. Onconetix had a negative net margin of 2,913.71% and a negative trailing twelve-month return on equity of 514.04%. When did Onconetix's stock split? Shares of Onconetix reverse split before market open on Friday, June 13th 2025.The 1-85 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Onconetix? Shares of ONCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Onconetix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Onconetix investors own include QUALCOMM (QCOM), Zura Bio (ZURA), Capital One Financial (COF), Lincoln National (LNC), Ovid Therapeutics (OVID), Plug Power (PLUG) and Sirius XM (SIRI). Company Calendar Last Earnings6/12/2025Today7/30/2025Next Earnings (Estimated)8/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ONCO Previous SymbolNASDAQ:ONCO CIK1782107 Webwww.bwbioinc.com Phone513-620-4101FaxN/AEmployees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.69 million Net Margins-2,913.71% Pretax Margin-2,961.68% Return on Equity-514.04% Return on Assets-75.82% Debt Debt-to-Equity RatioN/A Current Ratio0.17 Quick Ratio0.16 Sales & Book Value Annual Sales$2.52 million Price / Sales0.76 Cash FlowN/A Price / Cash FlowN/A Book Value$11.22 per share Price / Book0.32Miscellaneous Outstanding Shares530,000Free Float516,000Market Cap$1.92 million OptionableN/A Beta3.38 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ONCO) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredStrange Investment Secret Predicts Market's Next Move?A strange market signal discovered before the Great Depression has predicted nearly every major financial even...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconetix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.